Influence Of Zoledronic Acid On Healing After Arthroskopic Repair Of Chronic Rotator Cuff Lesions A Prospective, Randomized, Placebo-Controlled Phase II Trial ZORRO

Lab values

•  Patients younger than 50 or older than 70 years of age  Pregnancy  Known allergy to zoledronic acid or other components of the medicinal product  Previous fracture of the affected shoulder  Previous surgery of the affected shoulder  Previous or existing bacterial infection of the affected shoulder  Rupture of more than two tendons in the affected shoulder (massive rotator cuff tear)  Isolated subscapularis tendon tear  Presence of glenohumeral osteoarthritis (Hamada type 3 or higher)  Diabetes mellitus (fasting glucose ≥ 126 mg/dl, HbA1C ≥ 6.5%)  Malignant tumor disease  Pathological dental status  Known disease that interferes with bone metabolism  Concomitant diseases that do not permit general anesthesia  Previous therapy with anti-osteoporotic drugs (bisphosphonates, denosumab, teriparatide)  Epilepsy  Claustrophobia  Chronic alcohol abuse  Drug abuse

•  Age between 50 and 70 years  Magnetic resonance imaging verified rotator cuff tear (within 6 months prior to surgery)  Rupture size with a maximum diameter of 3 cm  Willingness to participate in the study  Willingness to participate in a unified physiotherapy with use of a shoulder abduction pad for four weeks postoperatively